DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.

ABSTRACT:

Background

DNA methylation-based tumor classification allows an enhanced distinction into subgroups of glioblastoma. However, the clinical benefit of DNA methylation-based stratification of glioblastomas remains inconclusive.

Methods

Multicentric cohort study including 430 patients with newly diagnosed glioblastoma subjected to global DNA methylation profiling. Outcome measures included overall survival (OS), progression-free survival (PFS), prognostic relevance of EOR and MGMT promoter methylation status as well as a surgical benefit for recurrent glioblastoma.

Results

345 patients (80.2%) fulfilled the inclusion criteria and 305 patients received combined adjuvant therapy. DNA methylation subclasses RTK I, RTK II, and mesenchymal (MES) revealed no significant surviv

SUBMITTER: Drexler R 

PROVIDER: S-EPMC9925709 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature